Modeling budgetary impact for decision makers.
The budgetary implications of using 5-HT3 receptor antagonists in the management of patients with chemotherapy-induced emesis is discussed. It was shown that treatment with 5-HT3 receptor antagonists in the acute phase of emesis resulted in relatively little additional cost when introduced into a normal management pattern of emesis control, and therefore seems justifiable. However, in delayed emesis there is a much more substantial budgetary impact with no proven clinical benefit, and therefore treatment does not appear to be appropriate in this situation.
Zammit-Lucia
J
J
Policy and Economics Group, St. John's Innovation Centre, Cambridge, UK.
D000465:Algorithms; D000932:Antiemetics / Q000191:economics* / Q000627:therapeutic use*; D002017:Budgets; D002986:Clinical Trials as Topic / Q000191:economics / Q000379:methods; D006801:Humans; D008962:Models, Theoretical; D012702:Serotonin Antagonists
D000932:Antiemetics; D012702:Serotonin Antagonists